What the Prior Auth Letter Writer actually produces

RE: Prior Authorization Request for [Patient Name] Dear Medical Director, I am writing to request expedited prior authorization for sacubitril/valsartan (Entresto) 97 mg/103 mg twice daily for my patient [Patient Name] with symptomatic heart failure with reduced ejection fraction (HFrEF), NYHA Class III functional limitation, and left ventricular ejection fraction (LVEF) of 30%. CLINICAL BACKGROUND The patient has been treated with enalapril 10 mg twice daily for 6 months without achieving adequate symptomatic control. Despite optimization on this ACE inhibitor, the patient experienced two hospitalizations for heart failure exacerbation in the past 12 months. Current medications include carvedilol 25 mg twice daily (well-tolerated) and spironolactone 25 mg daily. The recent hospitalization occurred within the past 30 days. CLINICAL RATIONALE According to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure (Class I, Level of Evidence A), ARNI (angiotensin receptor-neprilysin inhibitor) therapy is recommended for patients with HFrEF who remain symptomatic on ACE inhibitor or ARB therapy. The PARADIGM-HF trial demonstrated a 20% relative risk reduction in cardiovascular death and HF hospitalization when sacubitril/valsartan was substituted for an ACE inhibitor in similar patient populations. This patient meets criteria for ARNI escalation: documented failure of 6 months of ACE inhibitor monotherapy, persistent NYHA Class III symptoms despite optimal beta-blocker and aldosterone antagonist therapy, and objective evidence of disease progression (recurrent hospitalizations). Transition to sacubitril/valsartan is expected to reduce rehospitalization risk, improve functional capacity and quality of life, and decrease overall healthcare costs through prevention of decompensation events. Urgency of Request Given the recent hospitalization and ongoing clinical deterioration despite current therapy, delayed treatment change carries substantial risk of further decompensation and hospitalization. Expedited approval is clinically warranted. I respectfully request expedited review and approval of this prior authorization. Please contact me at [Provider Contact] with any questions regarding clinical necessity or patient-specific factors. Sincerely, [Pharmacist Name] [Credentials] [Contact Information]

Patient with NYHA Class III HFrEF (LVEF 30%) has failed 6 months of enalapril therapy, experiencing two HF-related hospitalizations despite optimization on beta-blocker and aldosterone antagonist. ACC/AHA/HFSA 2022 guidelines (Class I, Level A) support ARNI therapy for symptomatic HFrEF patients after ACE inhibitor failure. Sacubitril/valsartan demonstrated 20% relative risk reduction in cardiovascular death and HF hospitalization versus ACE inhibitor in PARADIGM-HF and is medically necessary to reduce rehospitalization risk.

• Patient has documented inadequate response to 6 months of ACE inhibitor (enalapril 10 mg twice daily) with persistent NYHA Class III symptoms and two HF-related hospitalizations in past 12 months • Current dual therapy (carvedilol 25 mg twice daily + spironolactone 25 mg daily) is appropriate but insufficient without ARNI escalation • ACC/AHA/HFSA 2022 Heart Failure Guidelines recommend ARNI therapy for HFrEF patients who remain symptomatic on ACE inhibitor (Class I, Level of Evidence A) • PARADIGM-HF trial demonstrated 20% relative risk reduction in cardiovascular death and HF hospitalization with sacubitril/valsartan versus enalapril • Recent hospitalization (within 30 days) and objective evidence of clinical deterioration support time-sensitive need for therapy optimization • Sacubitril/valsartan is expected to improve functional capacity, reduce hospitalization risk, and improve long-term quality of life